{"id":"placebo-matched-to-fenebrutinib","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T12:30:29.359968","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fenebrutinib inhibits BTK, a key enzyme in B-cell receptor and Toll-like receptor signaling pathways. By blocking BTK, it reduces the activation and proliferation of B cells and other immune cells involved in autoimmune and inflammatory responses. As a placebo matched to fenebrutinib, this arm contains no active drug and serves as a control comparator in clinical trials.","oneSentence":"This is a placebo control arm matched to fenebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell and myeloid cell activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:55.264Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 trials for fenebrutinib-targeted indications (likely autoimmune/inflammatory conditions)"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT04544449","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-26","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":985},{"nctId":"NCT04586023","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-24","conditions":"Relapsing Multiple Sclerosis","enrollment":751},{"nctId":"NCT04586010","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-17","conditions":"Relapsing Multiple Sclerosis","enrollment":746},{"nctId":"NCT02908100","phase":"PHASE2","title":"A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2017-01-19","conditions":"Systemic Lupus Erythematosus","enrollment":260},{"nctId":"NCT03137069","phase":"PHASE2","title":"A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2017-05-26","conditions":"Urticaria","enrollment":134},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT03188783","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-24","conditions":"Healthy Volunteer","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matched to fenebrutinib","genericName":"Placebo matched to fenebrutinib","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm matched to fenebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell and myeloid cell activation. Used for Control arm in phase 3 trials for fenebrutinib-targeted indications (likely autoimmune/inflammatory conditions).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}